Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors

Universal off-the-shelf combination immunotherapy using oncolytic viruses to redirect T cell engagers to target solid tumors

Background Bispecific T cell engager (BiTE), such as blinatumomab, has demonstrated significant clinical success in treating hematological malignancies like B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, the application of BiTEs in solid tumors has proven challenging,...

Full description

Saved in:
Bibliographic Details
Main Authors: Stephen J Forman, Wen-Chung Chang, Xiuli Wang, Anthony K Park, Ryan Urak, Yuman Fong, Monil Shah, Colin Cook, Yukiko Yamaguchi, Saul J Priceman, Cathy Lu, Shyambabu Chaurasiya, Isabel Monroy, Yuwei Ren, Hannah Valencia, Jackson Lent-Koop, Seonah Kang, Lupita Lopez, John P Murad, Leslie Mi Ok Chong
Format: Article
Language:English
Published: BMJ Publishing Group 2025-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/8/e011051.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items